Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

1.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapt Therapeutics Inc

< Previous 1 2 3 4 5 Next >
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for RAPT Therapeutics
Via Benzinga
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for RAPT Therapeutics's Future
Via Benzinga
Recap: RAPT Therapeutics Q1 Earnings
Via Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About RAPT Therapeutics
Via Benzinga
4 Analysts Have This to Say About RAPT Therapeutics
Via Benzinga
RAPT Therapeutics Reports First Quarter 2023 Financial Results
Company maintains strong cash position of $231.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket
Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday. 
Via Benzinga
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
Via Benzinga
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
From RAPT Therapeutics, Inc.
Via GlobeNewswire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
S&P 500 Rises 1%; Crude Oil Down Over 4%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1.5% on Tuesday. The Dow traded up 0.40% to 31,945.39 while the NASDAQ rose 1.58% to 11,365.53. The S&P 500,... 
Via Benzinga
Dow Extends Rebound, Surges 456 Points
Rallying bank stocks are fueling Wall Street's midday gains, as investors continue to unpack this morning's consumer price index (CPI) data. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Jumps Over 200 Points; GitLab Shares Plummet
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 400 points on Tuesday. The Dow traded up 1.30% to 32,234.35 while the NASDAQ rose 2.07% to 11,421.23. The S&P 500,... 
Via Benzinga
Dow Surges Over 300 Points; US Inflation Rate Drops To 6%
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1.03% to 32,145.42 while the NASDAQ rose... 
Via Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
Company maintains strong cash position of $249.1 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
Data Presented at ESMO Immuno-Oncology Congress 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
From RAPT Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.